<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00842465</url>
  </required_header>
  <id_info>
    <org_study_id>P070608</org_study_id>
    <nct_id>NCT00842465</nct_id>
  </id_info>
  <brief_title>Prolactin Receptor and Breast Diseases</brief_title>
  <acronym>Prolacsein</acronym>
  <official_title>Characterization and Implication of Prolactin Receptor Mutants in Human Breast Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prolactin is known to play an important role in breast development and differentiation. Thus
      proliferative breast diseases are good models to unravel PRl / PRLR function in proliferative
      processes.

      The aim of this project is to identify and to characterize new mutants of the prolactin
      receptor gene within cohorts of benign or malign breast diseases with low or high occurrence
      frequency in human populations
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is currently no known genetic disease linked to prolactin (prl) or its receptor (prlR)
      in humans. In a previous work, we have identified a new mutation of prolactin receptor that
      leads to it's constitutive activation and to cell proliferation signalling cascades (i.e.
      through MAP kinases).

      This result suggests that PRLR mutants may have a strong physiopathological impact on breast
      diseases etiology and/or development and/or evolution.

      Based on this, we will pursue the identification of new PRLR mutants in various breast
      diseases and continue their in vitro functional characterization and then analyse their in
      vivo consequences on breast tissue samples collected within these women.

        1. In a first time we wish to confirm our previous results on multiple fibroadenomas (MFA).
           The current cohort will be augmented with 30 to 35 new patients each year. We will
           confirm our in vitro results in vivo with tumoral and peri-tumoral tissue samples.

        2. We then wish to extend this study to other rare breast pathologies (i.e. gigantomastia,
           phyllodies tumors, giant fibroadenomas) and to more common ones (simple fibroadenomas)
           to demonstrate a link between simple FA and MFA.

        3. in a third time we will try to determinate whether a constitutive activation of PRLR
           leads to enhanced occurrence of benign / malign transitions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sequencing of PRLR</measure>
    <time_frame>at inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Breast ultrasonography</measure>
    <time_frame>at inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast MRI</measure>
    <time_frame>at inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic ultrasonography</measure>
    <time_frame>at inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density measurement</measure>
    <time_frame>at inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormonal and metabolic evaluation</measure>
    <time_frame>at inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological analysis of tumoral and peri-tumoral tissues</measure>
    <time_frame>at surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor transcriptome analysis</measure>
    <time_frame>at surgery</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">735</enrollment>
  <condition>Benign Breast Disease</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>benign breast diseases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>breast cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>control</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood collection for hormonal status analysis</intervention_name>
    <description>for hormonal status analysis</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>breast Biopsy or surgery</intervention_name>
    <description>breast Biopsy or surgery</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>blood collection</intervention_name>
    <description>blood collection for prlR gene sequencing</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ultrasonography (pelvis and breast), bone mineral density</intervention_name>
    <description>ultrasonography (pelvis and breast), bone mineral density</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood collection breast Biopsy or surgery
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Benign breast diseases(60 simple FA, 71 other breast diseases) Brest Cancer : 132 Control :
        525
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  benign breast diseases

               -  10 &lt; age &lt; 25 for simple FA

               -  10 &lt; age &lt; 50 for other diseases .no hormonal treatment for at least 3 months if
                  patients took cyproterone acetate; 1 month for other ovaries-interfering hormonal
                  treatment, and 1 week for ovaries-non-interfering hormonal treatments.

               -  Signature of the informed consent form (icf) by patients or their legal
                  representative (for patients under age of 18.)

          -  breast cancer :

               -  having a breast cancer with a planned surgery

               -  age &gt; 55 years

               -  post menopausal with not menopause substitution treatment

               -  signature of the icf

          -  control group :

               -  18 &lt; age &lt; 60

               -  signature of the icf

        Exclusion criteria :

          -  no signature or no conformity of the icf

          -  no social security
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Touraine, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pitié Salpêtrière Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2009</study_first_submitted>
  <study_first_submitted_qc>February 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2009</study_first_posted>
  <last_update_submitted>November 21, 2013</last_update_submitted>
  <last_update_submitted_qc>November 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast diseases,</keyword>
  <keyword>human mutation,</keyword>
  <keyword>prolactin receptor;</keyword>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Diseases</mesh_term>
    <mesh_term>Fibrocystic Breast Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

